Evaluation of adalimumab therapy in multidisciplinary strategy for perianal Crohn's disease patients with infliximab failure

Journal of Crohn's and Colitis

Volumn 4, Issue 6, 2010, Pages 654-660

  Echarri, Ana ^a   Castro, Javier ^a   Barreiro, Manuel ^b   Carpio, Daniel ^c   Pereira, Santos ^c   Lorenzo, Aurelio ^c  

^a Universidad de La Coruña   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c Gastroenterology Department   (Spain)

Author keywords

Adalimumab; Infliximab; Magnetic resonance imaging; Perianal Crohn's disease; Seton

Indexed keywords

ADALIMUMAB; INFLIXIMAB; PARACETAMOL;

ADULT; ANUS FISTULA; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DERMATITIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG INDUCED HEADACHE; FEMALE; GENERAL ANESTHESIA; HUMAN; MAINTENANCE THERAPY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROCTITIS; PROSPECTIVE STUDY; REMISSION; SURGICAL DRAINAGE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; CROHN DISEASE; DRAINAGE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PROSPECTIVE STUDIES; RECTAL FISTULA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 78649518358     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2010.07.012     Document Type: Article

References (29)

1. Schwartz D.A., Loftus E.V., Tremaine W.J., Panaccione R., Harmsen W.S., Zinsmeister A.R., et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002, 122:875-880.
2. Thia K.T., Mahadaven U., Feagen B.G., Wong C., Cockeram A., Bitton A., et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm. Bowel Dis. 2009, 15:17-24.
3. Pearson D.C., May G.R., Fick G.H., Sutherland L.R. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann. Intern. Med. 1995, 123:132-142.
4. Present D.H., Rutgeers P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J. Med. 1999, 340:1398-1405.
5. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J. Med. 2004, 350:876-885.
6. Van Assche G., Vanbeckevoort D., Bielen D., Coremans G., Aerden I., Noman M., et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am. J. Gastroenterol. 2003, 98:332-339.
7. Van Bodegraven A.A., Sloot C.E., Felt-Bersma R.J., Meuwissen S.G. Endosonographic evidence of persistence of Crohn's disease associated fistulas after infliximab treatment, irrespective of clinical response. Dis. Colon Rectum 2002, 45:39-46.
8. Schwartz D., White C., Wise P., Herline A.J. Use of endoscopic ultrasound to guide combination medical and surgical therapy for patients with Crohn's perianal fistulas. Inflamm. Bowel Dis. 2005, 11:727-732.
9. Topstad D.R., Panaccione R., Heine J.A., Johnson D.R., MacLean A.R., Buie W.D. Combined seton placement, infliximab infusion and maintenance immunosuppressives improve healing rate in fistulising anorectal Crohn's disease: a single center experience. Dis. Colon Rectum 2003, 46:577-583.
10. Regueiro M., Mardini H. Treatment of perianal fistulising Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm. Bowel Dis. 2003, 9:98-103.
11. Sandborn W.J., Hanauer S., Loftus E., Tremaine W.J., Kane S., Cohen R., et al. An open label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am. J. Gastroenterol. 2004, 99:1984-1989.
12. Hinojosa J., Gomollón F., García S., Bastida G., Cabriada J.L., Saro C., et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment. Pharmacol. Ther. 2007, 25:409-418.
13. Peyrin-Biroulet L., Laclotte C., Bigard A. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment. Pharmacol. Ther. 2007, 25:675-680.
14. Colombel J.F., Sandborn W.J., Rutgeerts P., Kamm M.A., Yu A.P., Wu E.Q., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
15. Colombel J.F., Schwartz D.A., Sandborn W.J., Kamm M.A., D'Haens G., Rutgeerts P., et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009, 58:940-948.
16. Baert F., Noman M., Vermeire S., Van Assche G., D' Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J. Med. 2003, 348:601-608.
17. Sandborn W.J., Fazio W.V., Feagan B.G., Hanauer S.B. AGA technical review on perianal Crohn's disease. Gastroenterology 2003, 125:1508-1530.
18. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., Macintosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
19. Irvine E.J. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. J. Clin. Gastroenterol. 1995, 20:27-32. Mc Master IBD Study Group.
20. Lichtenstein G., Yang S., Bala M., Blank M., Sands B.E. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005, 128:862-869.
21. Chapple K.S., Spencer J.A., Windsor A.C.J., Wilson D., Ward J., Ambrose N.S. Prognostic value of magnetic resonance imaging in the management of fistula-in-ano. Dis. Colon Rectum 2000, 43:511-516.
22. Schwartz D.A., Wiersema M.J., Dudiak K.M., Fletcher J.G., Clain J.E., Tremaine W.J., et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology 2001, 121:1064-1072.
23. Buchanan G., Halligan S., Williams A., Cohen C.R., Tarroni D., Phillips R.K., et al. Effect of MRI on clinical outcome of recurrent fistula-in-ano. Lancet 2002, 360:1661-1662.
24. Ardizzone S., Maconi G., Colombo E., Manzionna G., Bollani S., Bianchi Porro G. Perianal fistulae following infliximab treatment. Clinical and endosonographic outcome. Inflamm. Bowel Dis. 2004, 10:91-96.
25. Takesue Y., Ohge H., Yokoyama T., Murakami Y., Imamura Y., Sueda T. Long-term results of seton drainage on complex anal fistulae in patients with Crohn's disease. J. Gastroenterol. 2002, 37:912-915.
26. Hyder S., Travis S., Jewell D., McC Mortensen N.J., George B.D. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis. Colon Rectum 2006, 49:1837-1841.
27. Spradlin N.M., Wise P.E., Herline A.J., Muldoon R.L., Rosen M., Schwartz D.A. A randomized prospective trial of endoscopic ultrasound to guide combination medical and surgical treatment for Crohn's perianal fistulas. Am. J. Gastroenterol. 2008, 103:2527-2535.
28. Schwartz D.A., Maltz B.E. Treatment of fistulizing inflammatory bowel disease. Gastroenterol. Clin. North Am. 2009, 38:595-610.
29. Ng S.C., Plamondon S., Gupta A., Burling D., Swatton A., Vaizey C.J., et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am. J. Gastroenterol. 2009, 104:2973-2986.